Vimirogant | AGN 242428 | VTP-43742 | CAS#1802706-04-2 | RORγt inhibitor

MedKoo Cat#: 555290 | Name: Vimirogant

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Vimirogant, also known as AGN-242428 and VTP-43742, is a potent, selective and orally active RORγt inhibitor for the treatment of autoimmune disorders, including multiple sclerosis and psoriasis.

Chemical Structure

Vimirogant

CAS#1802706-04-2 (free base)

Theoretical Analysis

MedKoo Cat#: 555290

Name: Vimirogant

CAS#: 1802706-04-2 (free base)

Chemical Formula: C27H35F3N4O3S

Exact Mass: 552.2382

Molecular Weight: 552.66

Elemental Analysis: C, 58.68; H, 6.38; F, 10.31; N, 10.14; O, 8.68; S, 5.80

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

2115761-82-3 (2HBr) 1802706-04-2 (free base)

Synonym

Vimirogant; VTP-43742; VTP 43742; VTP43742; AGN-242428; AGN242428; AGN 242428.

IUPAC/Chemical Name

(S)-N-((5-(ethylsulfonyl)pyridin-2-yl)methyl)-7-isopropyl-6-(((1r,4S)-4-(trifluoromethyl)cyclohexyl)methyl)-6,7-dihydro-5H-pyrrolo[3,4-b]pyridine-3-carboxamide

InChi Key

XUYMIRYNRKXKOR-HMHJJOSWSA-N

InChi Code

InChI=1S/C27H35F3N4O3S/c1-4-38(36,37)23-10-9-22(31-14-23)13-33-26(35)19-11-20-16-34(25(17(2)3)24(20)32-12-19)15-18-5-7-21(8-6-18)27(28,29)30/h9-12,14,17-18,21,25H,4-8,13,15-16H2,1-3H3,(H,33,35)/t18-,21-,25-/m0/s1

SMILES Code

O=C(C1=CN=C([C@H](C(C)C)N(C[C@H]2CC[C@H](C(F)(F)F)CC2)C3)C3=C1)NCC4=NC=C(S(=O)(CC)=O)C=C4

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 552.66 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Gege C. RORγt inhibitors as potential back-ups for the phase II candidate VTP-43742 from Vitae Pharmaceuticals: patent evaluation of WO2016061160 and US20160122345. Expert Opin Ther Pat. 2017 Jan;27(1):1-8. doi: 10.1080/13543776.2017.1262350. Epub 2016 Nov 25. PMID: 27852111. 2: Gege C. Retinoid-related orphan receptor gamma t (RORγt) inhibitors from Vitae Pharmaceuticals (WO2015116904) and structure proposal for their Phase I candidate VTP-43742. Expert Opin Ther Pat. 2016 Jun;26(6):737-44. doi: 10.1517/13543776.2016.1153066. Epub 2016 Mar 4. PMID: 26895086. 3: Pandya VB, Kumar S, Sachchidanand, Sharma R, Desai RC. Combating Autoimmune Diseases With Retinoic Acid Receptor-Related Orphan Receptor-γ (RORγ or RORc) Inhibitors: Hits and Misses. J Med Chem. 2018 Dec 27;61(24):10976-10995. doi: 10.1021/acs.jmedchem.8b00588. Epub 2018 Jul 30. PMID: 30010338. 4: Gege C. Retinoic acid-related orphan receptor gamma t (RORγt) inverse agonists/antagonists for the treatment of inflammatory diseases - where are we presently? Expert Opin Drug Discov. 2021 Dec;16(12):1517-1535. doi: 10.1080/17460441.2021.1948833. Epub 2021 Jul 7. PMID: 34192992. 5: Balogh EA, Bashyam AM, Ghamrawi RI, Feldman SR. Emerging systemic drugs in the treatment of plaque psoriasis. Expert Opin Emerg Drugs. 2020 Jun;25(2):89-100. doi: 10.1080/14728214.2020.1745773. Epub 2020 Mar 31. PMID: 32192366. 6: Lu B, Liu D, Gui B, Gou J, Dong H, Hu Q, Feng J, Mao Y, Shen X, Wang S, Zhang C, Shen R, Yan Y, Chen L, Wang H, Li D, Zhang J, Zhang M, Zhang R, Bai C, He F, Tao W, Liu S. Discovery of 2-(Ortho-Substituted Benzyl)-Indole Derivatives as Potent and Orally Bioavailable RORγ Agonists with Antitumor Activity. J Med Chem. 2021 Oct 28;64(20):14983-14996. doi: 10.1021/acs.jmedchem.1c00828. Epub 2021 Oct 13. PMID: 34643383. 7: Chen L, Su M, Jin Q, Wang CG, Assani I, Wang MX, Zhao SF, Lv SM, Wang JW, Sun B, Li Y, Liao ZX. Discovery of N-(2-benzyl-4-oxochroman-7-yl)-2-(5-(ethylsulfonyl) pyridin-2-yl) acetamide (b12) as a potent, selective, and orally available novel retinoic acid receptor- related orphan receptor γt inverse agonist. Bioorg Chem. 2022 Feb;119:105483. doi: 10.1016/j.bioorg.2021.105483. Epub 2021 Nov 17. PMID: 34906860. 8: Zou H, Yang Y, Shi Z, Wu X, Liu R, Yu AM, Chen HW. Nuclear receptor RORγ inverse agonists/antagonists display tissue- and gene-context selectivity through distinct activities in altering chromatin accessibility and master regulator SREBP2 occupancy. Pharmacol Res. 2022 Aug;182:106324. doi: 10.1016/j.phrs.2022.106324. Epub 2022 Jun 21. PMID: 35750301; PMCID: PMC10158160.